The Fourth Clinical Medical School, Guangzhou University of Chinese Medicine, Shenzhen, China.
Department of Science and Education, Shenzhen Traditional Chinese Medicine Hospital, Shenzhen, China.
Biosci Rep. 2021 Jun 25;41(6). doi: 10.1042/BSR20204312.
C-x-C motif chemokine ligands (CXCLs) are critical regulators of cancer immunity and angiogenesis, which affect disease progression and treatment responses. The character of each CXCL in the prognosis and immune infiltration of hepatocellular carcinoma (HCC) patients is unclear yet.
Differentially expressed CXCLs between HCC and normal control were screened by Oncomine and GEPIA2. Genetic alternations of CXCLs in HCC were analyzed by cBioPortal. Clinicopathological relevance of CXCLs in HCC patients was analyzed using UALCAN. The prognostic value of CXCLs was evaluated using univariate and multivariate analyses. Correlations of CXCLs' expression with immune infiltration, chemokines and their receptors were assessed integrating TIMER, TISIDB, and GEPIA2. The co-expressed genes of CXCLs were discovered, and functional enrichment analysis was performed for them.
CXCL9/10 was significantly higher expressed while CXCL2/12/14 was lower expressed in HCC than normal tissues, but they didn't show significant clinicopathological relevance in HCC patients. High-expression of CXCL2/10/12/14 indicated favorable outcomes of HCC patients. The expression of CXCL9/10/12/14 was significantly positively correlated with not only the infiltration and biomarkers' expression of various tumor-infiltrating immune cells but also the abundance of chemokines and their receptors. The co-expressed genes of the five CXCLs were extracellular components and regulated immune or inflammatory responses and signaling pathways of chemokine, Toll-like receptor and tumor necrosis factor might be involved.
The present study proposed CXCL2/10/12/14 might predict outcomes of HCC patients and were extensively related with the immune microenvironment in HCC. It would be a prospective therapeutic strategy for HCC to enhance effective immunity surveillance through intervening in these CXCLs.
C-x-C 基序趋化因子配体 (CXCLs) 是癌症免疫和血管生成的关键调节剂,影响疾病进展和治疗反应。每个 CXCL 在肝细胞癌 (HCC) 患者中的预后和免疫浸润特征尚不清楚。
通过 Oncomine 和 GEPIA2 筛选 HCC 与正常对照之间差异表达的 CXCL。通过 cBioPortal 分析 HCC 中 CXCL 的遗传改变。使用 UALCAN 分析 HCC 患者中 CXCL 的临床病理相关性。使用单因素和多因素分析评估 CXCL 的预后价值。通过 TIMER、TISIDB 和 GEPIA2 整合评估 CXCL 表达与免疫浸润、趋化因子及其受体的相关性。发现 CXCL 的共表达基因,并对其进行功能富集分析。
与正常组织相比,CXCL9/10 在 HCC 中表达显著升高,而 CXCL2/12/14 表达降低,但在 HCC 患者中它们与临床病理无关。CXCL2/10/12/14 高表达提示 HCC 患者预后良好。CXCL9/10/12/14 的表达与各种肿瘤浸润免疫细胞的浸润和标志物表达以及趋化因子及其受体的丰度呈显著正相关。这五个 CXCL 的共表达基因是细胞外成分,调节免疫或炎症反应,趋化因子、Toll 样受体和肿瘤坏死因子信号通路可能参与其中。
本研究提出 CXCL2/10/12/14 可能预测 HCC 患者的预后,并与 HCC 中的免疫微环境广泛相关。通过干预这些 CXCL 来增强有效的免疫监测可能成为 HCC 的一种有前景的治疗策略。